Mydalyn Beronilla

Towards a translational computational model of allergen challenge in mild asthma to support clinical development of an intranasal administration of a bacterial lysate

Rationale The risk of biologics targeting type 2 inflammation in asthmatics for experiencing morbidity or mortality from COVID-19 infection is uncertain. We examined COVID-19 infection outcomes in inner city asthmatics treated with biologics. Methods We conducted a retrospective study of COVID 19 outcomes in primarily moderate to severe inner-city asthmatics receiving biologics, who were followed in Allergy/Immunology practice of Montefiore Medical Center.